Inhibition of ATG4B enhances PRMT1‐MRE11‐mediated DNA damage responses, promotes S‐phase checkpoint activation, and induces robust S‐to‐G2/M cell cycle arrest in AML cells. The gene discussed is ATG4B; the disease is acute myeloid leukemia.